dkNET community events and announcements in November, 2021

Dear dkNET Community,

dkNET provides updates on activities of interest to the NIDDK-supported community. You could keep up to date on these activities through our Twitter feed @dkNET_info, through our Community Calendar, or through dkNET e-mail list. If you have an event or funding opportunities you'd like to advertise, please contact us info_at_dknet.org.

Events in October 2021

Nov. 01-04, 2021

NIH Virtual Seminar on Program Funding & Grants Administration

Learn about NIH grant processes, policies, and programs. Interact with NIH program, grants management, review and policy staff. Engage and network with your peers. 

Join the virtual seminar on Nov. 1-4, 2021. Register for free at the link below. 

More Information: https://grants.nih.gov/2021-nih-virtual-seminar.htm

Nov. 01-04, 2021 

18th Immunology of Diabetes Society Congress

The Immunology of Diabetes Society (IDS) is dedicated to improving our understanding of the pathogenesis and treatment of type 1 diabetes. At the Congress, scientists will present the latest research related to the immunology of type 1 diabetes. The meeting will also be a platform for discussions on rapidly evolving topics and will provide opportunities to interact with scientific colleagues. 

Location: Nashville, TN

More Information: https://www.idsnashville2021.org/

Nov. 03-05, 2021 

Western Region Islet Study Group 2021 Meeting

The Western Region Islet Study Group (WRISG) 2021 meeting aims to bring together trainees and faculty studying islet biology to share their discoveries, enhance interactions, and encourage collaboration in diabetes across western Canada and the USA. Any research in islet biology is welcome. This meeting is being organized by the Diabetes Research Center at University of Washington with financial support from industry partners.

Location: Stevenson, WA

More information https://depts.washington.edu/diabetes/western-region-islet-study-group/

Nov. 04-07, 2021 

American Society of Nephrology KIDNEY WEEK 2021

Kidney Week 2021 is comprised of: (1) 6 Early Programs (fully virtual): On-demand presentations available on Monday, October 25, 2021. Live-stream sessions on Wednesday, October 27, 2021, and Thursday, October 28, 2021. Each program addresses a specific topic in nephrology and requires separate registration. (2) Annual Meeting (hybrid): Thursday, November 4, 2021, through Sunday, November 7, 2021. In-person and virtual sessions, posters, exhibits, networking activities, and more.

Location: San Diego, CA

More information: https://www.asn-online.org/

Nov. 08-12, 2021

MMPC Isotope Tracers in Metabolic Research Course: Principles and Practice of Kinetic Analysis

The 13th Annual Isotope Tracers in Metabolic Research Course will occur this year with limited capacity. Once you complete and submit your registration, the course directors and administrators will review your application. 

More Information: https://www.mmpc.org/shared/courses.aspx#tracers

Nov. 09, 2021 

Endocrine Society Insulin 2121: The Next 100 Years of Discoveries

The Society's free half-day educational event on the future of insulin features top researchers and clinicians to discuss the technology and therapies that will transform the field over the next 100 years. Research into robots that would automate routine tasks and free up clinicians’ time, next-gen glucagon, and weekly insulin injections are just a few of the innovative topics being discussed. Virtual Insulin 2121 takes place on Nov. 9, 11am-2:30pm EST (8am-11:30am PST)

More Information: https://www.endocrine.org/membership/100-years-of-insulin/100-years-events

Nov. 10, 2021 

Abstract Submission Deadline: Keystone Symposium Adipose Tissue and Metabolic Health

Like the obesity and Type 2 epidemic, our understanding of adipocytes and adipose tissue biology continues to expand. Substantial research advances have led to new insights into the contributions of adipose tissue to normal physiology and obesity-related complications, which places adipocyte biology at the epicenter of a global pandemic of metabolic diseases. Our proposed Keystone Symposia conference “Adipose Tissue and Metabolic Health” will consider the locations and functions of different adipose tissue depots, as well as recent studies that use stable isotopies to provide insight into how formation and turnover of adipocyte contributes to metabolic diseases. The secretory capacities of adipose tissue will be covered in several different sessions including “Influences of Adipose Tissue Immune Cells” and “New Adipose Tissue Products-Exosomes and Lipid Containing Vesicles”. Conference Dates: February 6-9, 2022

Location: Keystone, CO, USA. Meeting is available as a Livestream and to view On Demand.

More Information: https://www.keystonesymposia.org/KS/Online/Events/2022Q2/Adipose-Tissue-Metabolic-Health.aspx?EventKey=2022Q2

Nov. 12, 2021 

dkNET Webinar “The Microphysiology Systems Database (MPS-Db): A Platform For Aggregating, Analyzing, Sharing And Computationally Modeling In Vitro Data”

The Microphysiology Systems Database Center (MPS-DbC) developed and implemented the Microphysiology Systems Database (MPS-Db, https://mps.csb.pitt.edu/) for the management, analysis, sharing, integration of preclinical and clinical information, and computational modeling of data in one platform, enhancing the in vitro model value and user workflow. The MPS-Db supports data from a wide range of in vitro models including static and microfluidic 2D and 3D microplates, and microfluidic MPS for single and multiple organ models. Aggregation of metadata, experimental data, and references provides for robust and relevant interpretation of the results, and having a central repository facilitates data sharing among user-specified collaborators and groups. Ready access to experimental data and metadata from any in vitro platform, along with reference data in a mineable format, provides a convenient platform for statistical analysis of performance, and building computational models to predict PK, identify compound mechanisms of actions, and infer pathways of disease progression. The MPS-DbC assists users in capturing and managing MPS data, and the MPS-Db is the central repository for the Tissue Chip Testing Centers, as well as the NCATS Tissue Chips programs. We continue to build the research and commercial value of the MPS-Db by: 1) supporting MPS users to build content; 2) implementing on-line preclinical/clinical concordance analysis capabilities; 3) enhancing the suite of data mining and computational modeling tools; and 4) augmenting methods for ensuring data quality and the secure, controlled release of data to user-specified groups.

Presenter:  Bert Gough, PhD, Association Professor of Computational and Systems Biology, Group Leader Informatics, University of Pittsburgh Drug Discovery Institute 

More Information: https://dknet.org/about/blog/2352

Nov. 18, 2021 

30th Annual Irwin M. Arias Symposium

The first Irwin M. Arias, M.D. Symposium was held in 1991, and the theme of the event was – as it remains today – Bridging Basic Science and Liver Disease. Our program will include 9 plenary talks, and a collection of ‘micro talks’ of just 3 minutes each – to be selected from registered abstract submissions. We will also feature a ‘fireside chat’ style discussion between Dr Arias and our current Symposium directors, Drs. Sangeeta Bhatia and Wolfram Goessling. Finally, we will leverage the power of digital conferencing technology to offer ‘meet the expert’ opportunities in which trainees can register to join small group discussions with our speakers and other distinguished scientists in our field. 

More Information: https://alfevents.org/ariassymposium/

Nov. 20, 2021 

Frontiers in Diabetes: Neural Control of Metabolic Homeostasis Conference

This virtual program is designed for research scientists, clinicians, and students with an interest in diabetes and obesity. Specifically, this conference will focus on recent basic and clinical insights regarding bidirectional crosstalk between the brain and peripheral tissues integral to maintaining body weight, glucose and lipid homeostasis. Particular emphasis will be placed on the interactions – and potential genetic mechanistic links – relating to susceptibility to development of obesity, diabetes and related dyslipidemias. Additional areas of focus will include novel potential approaches to the treatment of these metabolic diseases.

More Information: https://dknet.org/about/dknetnews/2282

Nov. 24, 2021 

LIPID MAPS Webinar: "Fluxolipidomics of lipid mediators and oxylipins in blood compartments"

Michel Lagarde is a University Professor Emeritus at INSA-Lyon (Lyon university), France. He started his research career at the Pasteur Institute of Lyon, localized in a University Hospital, then spent around ten years as a researcher at Inserm, the French Medical Research Council/National Institute of Health, before having a university position to teach structural and metabolic biochemistry and pursuing his research on lipids. His research interest relates with membrane lipids and lipid mediators generated in blood and vascular cells, in response to specific activators, especially in the context of aging and diabetes mellitus. These lipid mediators are mainly oxygenated derivatives of polyunsaturated fatty acids of nutritional value. Tune into the webinar on November 24, 2021 at 5pm GMT | 9am PST | 12pm EST

Presented by: Professor Michel Lagarde

More Information: https://www.lipidmaps.org/resources/webinars/16

Nov. 30, 2021 

Abstract Submission Deadline: Experimental Biology 2022

EB welcomes research in all areas of experimental biology — in particular, anatomy, biochemistry and molecular biology, investigative pathology, pharmacology and physiology. Join the community that brings together scientists of all career levels to share cutting?edge research, networking and career advancement. It all starts with submitting an abstract on your latest research. Conference dates: April 2-5, 2022

More Information: https://www.experimentalbiology.org/abstracts

Nov. 30, 2021 

Scholarship Deadline: Keystone Symposia Gut-Brain Axis

The gut-brain axis encompasses bidirectional communication between the gastrointestinal tract and the central nervous system (CNS). This is mediated via the autonomic nervous system, including the vagus nerve and enteric nervous system (ENS), and endocrine, immune, and metabolic pathways. These systems coordinate physiology and behavior in health and disease. The underlying mechanisms and pathways are now being elucidated in this emerging area of scientific interest. Understanding the gut-brain axis augments neurobiological mechanisms and provides opportunities to treat CNS disorders from the periphery as well as metabolic and immunologic diseases. This meeting will bring together basic and applied scientists from across academia and industry to advance our understanding of gut-brain signaling.Conference Dates: March 20-23, 2022; Abstract Deadline: December 7 2021.

More Information: https://www.keystonesymposia.org/KS/Online/Events/2022X6/Gut-Brain-Axis.aspx?EventKey=2022X6%20%20

Funding Opportunities Information and Deadlines in November 2021

Nov. 01, 2021 

NHGRI Funding Opportunity Application Due: Molecular Phenotypes of Null Alleles in Cells (MorPhiC) Phase 1: Data Production Research and Development Centers (UM1 Clinical Trial Not Allowed)

This FOA is one of three issued to create a new program called "Molecular Phenotypes of Null Alleles in Cells (MorPhiC)". The long-term goal of MorPhiC is to develop a consistent catalog of molecular and cellular phenotypes for null alleles for every human gene, using in vitro multicellular systems. The catalog will be made available for broad use by the biomedical community. The program will start with a Phase 1 to optimize available methods to create null alleles and measure their phenotypic effects in a target subset of 1000 protein coding genes across the program. Phase 1 will also assess the scale limitations of such methods, develop common data formats, establish “use cases” for this catalog, and inform whether and how a potential second phase will be implemented. This specific FOA seeks applications for MorPhiC Data Production Research and Development Centers, which will develop diverse systems and assays and explore and compare approaches to produce MorPhiC data at scale, and to maximize its informativeness.

More Information: https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-21-029.html

Nov. 01, 2021 

NHGRI Funding Opportunity Application Due: Molecular Phenotypes of Null Alleles in Cells (MorPhiC) Phase 1: Data Analysis and Validation Centers (U01 Clinical Trial Not Allowed)

This FOA is one of three issued to create a new program called "Molecular Phenotypes of Null Alleles in Cells (MorPhiC)". The long-term goal of MorPhiC is to develop a consistent catalog of molecular and cellular phenotypes for null alleles for every human gene, using in vitro multicellular systems. The catalog will be made available for broad use by the biomedical community. The program will start with a Phase 1 to optimize available methods to create null alleles and measure their phenotypic effects in a target subset of 1000 protein coding genes across the program. Phase 1 will also assess the scale limitations of such methods, develop common data formats, establish “use cases” for this catalog, and inform whether and how a potential second phase will be implemented. This specific FOA seeks applications for MorPhiC Data Analysis and Validation Centers. These Centers will develop computational models and data analysis and visualization methods to evaluate and help ensure the utility of the MorPhiC data. Separate FOAs will be issued for the two other components of MorPhiC: Data Production Research and Development Centers and a Data Resource and Administrative Coordination Center to receive, annotate, and present data for consortium and public use and to be the administrative coordinating center for the MorPhiC consortium. 

More Information: https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-21-030.html 

Nov. 03, 2021 

NIDDK Funding Opportunity Application Due: Biomarkers for Diabetic Foot Ulcers through the Diabetic Foot Consortium (R61/R33 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement is to promote the development of prognostic, monitoring, and diagnostic biomarkers for diabetic foot ulcers that can be used in clinical trials and patient care. This initiative will support early analytical and clinical validation of biomarkers through a phased award to encourage innovative research. The initiative will leverage the resources of the Diabetic Foot Consortium to facilitate the access to well-characterized patients and high-quality human samples. The goal of this initiative is to deliver candidate biomarkers that are ready for definitive analytical and clinical validation studies through the Diabetic Foot Consortium. 

More Information:  https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-001.html

Nov. 03, 2021 

NIDDK Funding Opportunity Application Due: Characterization of Islet-derived Extracellular Vesicles for Improved Detection, Monitoring, Classification, and Treatment of Type 1 Diabetes (R01 Clinical Trial Not Allowed)

This initiative will support the development of tools and experimental platforms for the purification and characterization of Extracellular Vesicles (EV) originating from the human pancreatic islet and its broader tissue environment in healthy individuals, and individuals with T1D or at-risk of developing the disease. It will also support the exploration of the contribution of pancreatic EV biology to islet function, dysfunction and T1D disease initiation; the development of EV-based diagnostic tools for disease monitoring and classification; and the use of pancreatic EV biology to identify novel therapeutic targets.

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-016.html

Nov. 08, 2021 

NIH Funding Opportunity Letter of Intent Due: HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)

The goals of this program are to support locally relevant research in critical areas of HIV-associated non-communicable diseases (NCDs) at Low- and Middle-Income Country (LMIC) Institutions, to enhance research capacity, and to build a network of researchers both within and across LMICs to address this critical burden. This initiative is expected to stimulate new research on the interplay between HIV and development of NCDs in persons living with HIV (PLWH). This includes exploratory studies to uncover the extent to which HIV infection influences the etiopathogenesis of the NCDs; and to identify and develop appropriate approaches for effective diagnosis, prevention, therapeutic interventions and integrated clinical care for PLWH with the comorbid conditions. Applicants should develop their studies in keeping with the NIH HIV/AIDS Research Priorities. Application Deadline: December 8, 2021

More Information: https://grants.nih.gov/grants/guide/pa-files/par-21-246.html

Nov. 09, 2021 

NIDDK Funding Opportunity: NIDDK Research Education Program Utilizing Stimulating Peripheral Activity to Relieve Conditions (SPARC) - Generated Resources (R25 Clinical Trial Not Allowed) Application Due Date

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: (1) Research Experiences (2) Courses for Skills Development. This Funding Opportunity Announcement (FOA) invites applications to establish research programs for qualified graduate students, post-doctoral fellows, medicalresidents, biomedical engineers, and clinical fellows to engage in neuroscience research experiences relevant to the mission of NIDDK and its partnership with the Common Fund program, Stimulating Peripheral Activity to Relieve Conditions (SPARC). The intent is to leverage this partnership to provide resources for short-term research experiences that would necessarily use SPARC-generated resources (datasets/maps/models) as the foundation for the research experience in conjunction with educational activities that may be combined with hands-on computational or ‘wet lab’ projects. The goal is that the research experiences will be impactful and ideally develop new skills and produce new knowledge that could sustain future NIDDK-funded research careers.

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-20-020.html

Nov. 09, 2021  (Remove)

NIH Funding Opportunity Application Due: Pediatric Obesity Discovery Science Research to Improve Understanding of Risk and Causal Mechanisms for Obesity in Early Life (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to accelerate development, testing and implementation of evidence-based interventions—that are culturally and linguistically appropriate for NIH-designated populations that experience health disparities (HDPs) in the United States—to mitigate disparities in provision of care and treatment decisions, reduce susceptibility to chronic pain and improve patient outcomes. Expected outcomes of this initiative include evidence-based interventions that mitigate: 1) the effects of bias, stigma and discrimination at multiple levels, and/or 2) socioeconomic, environmental and other barriers to quality pain assessment, treatment and management. Studies that address multiple socioecological domains and levels of influence (e.g. organizational/institutional, community/neighborhood, societal) to advance health equity and mitigate health disparities in pain management are of higher priority. Studies must address research topics within the mission and research interests of participating NIH Institutes and Centers.

Letter of Intent Deadline: 30 days prior to the application due date

Application Deadline: December 9, 2021

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-ns-22-002.html

Nov. 15, 2021 

NIDDK Funding Opportunity Application Due: Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for PA-20-222: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed) 

The NIH has a strong interest in the diversity of the NIH-funded research enterprise (see NIH notice NOT-OD-20-031) and encourages institutions to diversify their scientific workforce by increasing the participation of individuals from groups identified as underrepresented in the biomedical, clinical, behavioral, and social sciences. Participating institutes continue to support these efforts through ongoing programs and supplement funding opportunities. This specific notice reiterates this interest and encourages eligible grant and cooperative agreement awardees in the HEAL Initiative community to apply for administrative supplements in response to PA-20-222 (or any subsequent reissuances), Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed). This notice is part of the NIH’s Helping to End Addiction Long-term (HEAL) Initiative to speed scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative is a trans-NIH effort to (1) improve prevention and treatment strategies for opioid misuse and addiction and (2) enhance pain management. More information about the HEAL Initiative is available at: https://heal.nih.gov/.

More Information: https://grants.nih.gov/grants/guide/notice-files/not-ns-20-107.html

Nov. 17, 2021 

NIDDK Funding Opportunity Application Due: Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support multidisciplinary research teams with complementary expertise in HIV and pathobiology, pathophysiology, and/or metabolism in organs, tissues, and/or biological systems of specific interest to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). These teams will comprehensively interrogate fundamental mechanisms underlying HIV-associated comorbidities, coinfections, and complications relevant to the mission of the NIDDK and advance progress toward alleviating them. 

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-20-022.html 

Nov. 18, 2021 

NIDDK Funding Opportunity Application Due: Pediatric Centers of Excellence in Nephrology (P50 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) invites applications for the Pediatric Centers of Excellence in Nephrology (PCEN) to support basic, translational and clinical research in pediatric kidney disease. The goals of this program are: 1. to attract new scientific expertise to the study of human pediatric renal physiology, kidney development, and pediatric kidney disorders; 2. to encourage multidisciplinary research in these areas; and 3. to develop the pediatric nephrology research community through a national research symposium, broad sharing of research resources, and a national Pilot and Feasibility grant program. These efforts are expected to lead to innovative approaches to study kidney disease in children and the eventual submission of substantial, competitive, investigator–initiated research applications. The PCEN will complement the O’Brien Kidney and Urological Research Centers and are expected to leverage existing institutional resources which may include Clinical Translational Science Awards, Institutional Network Awards for Promoting Kidney, Urologic, and Hematologic Research Training (U2C/TL1), and other NIDDK-Division of Kidney, Urologic and Hematologic Diseases (KUH)-funded consortia.

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-024.html

Nov. 18, 2021 

NIDDK Funding Opportunity Application Due: National Program for the Career Development Of Physician Scientists in Diabetes Research (Diabetes - Docs) (K12 Clinical Trial Optional)

The purpose of the Diabetes-Docs Program is to support the career development of physicians committed to a career in diabetes research. The program is intended to remedy the dearth of pediatric endocrinologists and physicians from other specialties conducting innovative research into the causes and consequences of diabetes. Diabetes-Docs will be a single national program, implemented by one or more PD/PIs, together with an advisory committee composed of basic and clinical investigators who have a strong record of funded research and successful training of physician-scientists. Although there will be one national administrative center awardee, scholars are expected to be appointed and supported at their home institutions around the country. The program will have a focus on Type 1 Diabetes (T1D) research, with the major funding from the Statutory Special Diabetes Program https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program. Starting in the second year, the program will expand to support the career development of physicians whose research focuses on innovative projects in type 2 diabetes. The program is expected to deliver on goals to increase the diversity of physician scientists with independent research careers in the mission of NIDDK https://www.niddk.nih.gov/research-funding/research-programs#diabetes.

This Funding Opportunity Announcement (FOA) allows appointment of Scholars (K12) proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-019.html

Nov. 19, 2021 

NIH Funding Opportunity Application Due: Tissue Mapping Centers for the Human BioMolecular Atlas Program (U54 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to establish state-of-the-art Tissue Mapping Centers (TMCs) that will generate a high-resolution, high-content, multiscale atlas of a non-diseased human organ. Centers will be expected to integrate and optimize all parts of the data generation pipeline, from tissue collection and preservation through to data integration, analysis and interpretation. Centers will also be expected to work closely with the other funded projects as part of the Human BioMolecular Atlas Program to catalyze development of a framework for mapping the human body in 3D with high resolution.

More Information: https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-21-026.html

Nov. 21, 2021 

NIDDK Funding Opportunity Letter of Intent Due: NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Genetic Research Centers (GRCs) (U01 Clinical Trial Optional)

The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) was established in July 2002 for the purpose of identifying genetic variation predisposing to Inflammatory Bowel Disease (IBD). Since its establishment and in collaboration with the International IBD Genetics Consortium, the NIDDK IBDGC has identified over 250 IBD susceptibility loci. However, for the great majority of these loci, the specific causal variants and effector genes have not yet been identified, and the biological mechanisms through which these variants influence IBD pathophysiology remain to be elucidated. The purpose of this Funding Opportunity Announcement (FOA) is to renew the IBDGC with a continued mission to characterize the genetic architecture of IBD phenotypes, particularly in populations currently underrepresented in IBD genomic studies, and to elucidate the biological mechanisms by which genetic variants influence IBD pathophysiology, phenotypes and clinical course. The Genetic Research Centers (GRCs) of the IBDGC will serve as sites for enrollment of IBD patients, relatives and healthy controls, for laboratory-based studies on biological samples obtained from these subjects, and for mechanistic studies of the risk variants identified, and of the genes, proteins and pathways they impact. Application Deadline: December 21, 2021

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-022.html

Nov. 30, 2021 

KPMP Funding Opportunity Application Due: Whole Genome Sequencing on KPMP Participants

Recent advances in multi-scale interrogation of human tissue and single cells have set the stage for precision medicine to be applied to kidney disease. The objectives of the KPMP are to ethically and safely obtain and evaluate human kidney biopsies from participants with Acute Kidney Injury (AKI) or Chronic Kidney Disease (CKD), create a kidney tissue atlas, define disease subgroups, and identify critical cells, pathways and targets for novel therapies.The purpose of this funding opportunity announcement is for the KPMP to solicit proposals from qualified institutions/companies to run whole genome sequencing on KPMP participant samples. 

More Information: https://www.kpmp.org/opportunity-pool

Nov. 30, 2021 

NIDDK Funding Opportunity Application Due: Advancing Gender Inclusive Excellence (AGIE) – Coordinating Center (U54 - Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to support a Coordinating Center (U54) for Advancing Gender Inclusive Excellence (AGIE). The Coordinating Center will provide the organizational framework for the management, direction, and overall coordination of all common activities aimed at investigating the strategies, approaches, barriers and interventions to women attaining leadership positions in many areas of science.

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-od-21-010.html